Compare IPHA & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPHA | EDAP |
|---|---|---|
| Founded | 1999 | 1979 |
| Country | France | France |
| Employees | N/A | 310 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.6M | 163.4M |
| IPO Year | N/A | 1998 |
| Metric | IPHA | EDAP |
|---|---|---|
| Price | $1.74 | $4.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $5.00 | ★ $8.50 |
| AVG Volume (30 Days) | 16.7K | ★ 80.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.31 | N/A |
| Revenue Next Year | N/A | $7.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $1.21 |
| 52 Week High | $2.63 | $5.05 |
| Indicator | IPHA | EDAP |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 50.12 |
| Support Level | $1.73 | $3.89 |
| Resistance Level | $1.90 | $5.05 |
| Average True Range (ATR) | 0.09 | 0.36 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 75.18 | 20.23 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.